Adequan® i.m. SINGLE DOSE
... PRECAUTIONS: The safe use of Adequan ® i.m. Multi-Dose in horses used for breeding purposes, during pregnancy, or in lactating mares has not been evaluated. ...
... PRECAUTIONS: The safe use of Adequan ® i.m. Multi-Dose in horses used for breeding purposes, during pregnancy, or in lactating mares has not been evaluated. ...
SPIRIVA® 18 microgram, inhalation powder, hard capsule
... significantly longer dissociation half-life than ipratropium. As an N-quaternary anticholinergic, tiotropium bromide is topically (broncho-) selective when administered by inhalation, demonstrating an acceptable therapeutic range before systemic anticholinergic effects may occur. Pharmacodynamic eff ...
... significantly longer dissociation half-life than ipratropium. As an N-quaternary anticholinergic, tiotropium bromide is topically (broncho-) selective when administered by inhalation, demonstrating an acceptable therapeutic range before systemic anticholinergic effects may occur. Pharmacodynamic eff ...
Cryopyrin-Associated Periodic Syndrome (CAPS) What is it
... reported symptoms include conjunctivitis and muscle pain. Symptoms usually begin 1–2 hours after generalized exposure to cold temperatures or to important variation of temperature, and the length of the attacks is usually short (less than 24 hours). These attacks are self-limited (meaning that they ...
... reported symptoms include conjunctivitis and muscle pain. Symptoms usually begin 1–2 hours after generalized exposure to cold temperatures or to important variation of temperature, and the length of the attacks is usually short (less than 24 hours). These attacks are self-limited (meaning that they ...
Antidepressant Choices in Primary Care
... insomnia, anxiety, and agitation (worse with fluoxetine). Paroxetine, due to its anticholinergic effects, generally is more likely to cause sedation. Taking SSRIs (except paroxetine) in the morning, starting at one-half of the lowest therapeutic dose and increasing it gradually minimizes this. Concu ...
... insomnia, anxiety, and agitation (worse with fluoxetine). Paroxetine, due to its anticholinergic effects, generally is more likely to cause sedation. Taking SSRIs (except paroxetine) in the morning, starting at one-half of the lowest therapeutic dose and increasing it gradually minimizes this. Concu ...
Adverse Reaction
... before subsequent doses are administered. Cisplatin-induced renal tubule damage can result in clinically significant hypomagnesemia and hypokalemia as well as hypocalcemia, hyponatremia, hypophosphatemia, and hyperuricemia ...
... before subsequent doses are administered. Cisplatin-induced renal tubule damage can result in clinically significant hypomagnesemia and hypokalemia as well as hypocalcemia, hyponatremia, hypophosphatemia, and hyperuricemia ...
APO-go® PEN
... Issue Date: September 2010 Approved by: GPMTC Page 1 of 5 Review Date: September 2012 ...
... Issue Date: September 2010 Approved by: GPMTC Page 1 of 5 Review Date: September 2012 ...
Narcan Overview - Telco House Bed & Breakfast
... push; repeat as indicated (per protocol) SC; repeat as indicated (per protocol) ...
... push; repeat as indicated (per protocol) SC; repeat as indicated (per protocol) ...
amphotericin B
... penetration. 2. Unlike other Azoles (ketoconazole and itraconazole), its oral bioavailavility is high. 3. Drug interactions are also less common because Fluconazole has the least effect of all the azoles on hepatic microsomal enzymes. ...
... penetration. 2. Unlike other Azoles (ketoconazole and itraconazole), its oral bioavailavility is high. 3. Drug interactions are also less common because Fluconazole has the least effect of all the azoles on hepatic microsomal enzymes. ...
Behavioral Effects of Long-Term Antimuscarinic Use in Patients with
... oxybutynin from birth onward. They were matched on a 1-to-1 basis by gender, age, type of lesion, presence of hydrocephalus and, if possible, by number of drain revisions. Patients used oxybutynin orally or intravesically. Both of these routes were included, since intravesical oxybutynin also enters ...
... oxybutynin from birth onward. They were matched on a 1-to-1 basis by gender, age, type of lesion, presence of hydrocephalus and, if possible, by number of drain revisions. Patients used oxybutynin orally or intravesically. Both of these routes were included, since intravesical oxybutynin also enters ...
![Mefenamic Acid tablets 500 mg BP [dtw]](http://s1.studyres.com/store/data/008012106_1-d03734e057378a8035fde5725d328ab3-300x300.png)
Mefenamic Acid tablets 500 mg BP [dtw]
... Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.2, and GI and cardiovascular risks below). Patients on prolonged therapy should be kept under regular surveillance with particular attention to liver dysfunc ...
... Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.2, and GI and cardiovascular risks below). Patients on prolonged therapy should be kept under regular surveillance with particular attention to liver dysfunc ...
animal models of human diseases and their significance for clinical
... This method cannot be applied if elimination in different species is different (drug metabolism, efflux or transporter binding). It can predict the average values of the pharmacokinetic parameters. The allometric approach is the best described technique for predicting human pharmacokinetics based o ...
... This method cannot be applied if elimination in different species is different (drug metabolism, efflux or transporter binding). It can predict the average values of the pharmacokinetic parameters. The allometric approach is the best described technique for predicting human pharmacokinetics based o ...
Rifampicin 150 mg + isoniazid 75 mg + ethambutol
... R150/H75/E275 is based on 2:1:3 dosing guidelines (IAP, Indian Pediatrics.net). Reduced dose E275 allows for more accurate dosing than E400mg (and E100mg) ...
... R150/H75/E275 is based on 2:1:3 dosing guidelines (IAP, Indian Pediatrics.net). Reduced dose E275 allows for more accurate dosing than E400mg (and E100mg) ...
Vetalog® Parenteral Surpass - Boehringer Ingelheim Vetmedica
... signs such as inappetence, colic, fecal abnormalities, anemia or depression are observed. As a class, NSAIDs may be associated with gastrointestinal and renal toxicity. When NSAIDs inhibit prostaglandins that cause inflammation, they may also inhibit prostaglandins that maintain normal homeostatic f ...
... signs such as inappetence, colic, fecal abnormalities, anemia or depression are observed. As a class, NSAIDs may be associated with gastrointestinal and renal toxicity. When NSAIDs inhibit prostaglandins that cause inflammation, they may also inhibit prostaglandins that maintain normal homeostatic f ...
medication in Parkinson`s disease
... when additional help is needed to control Parkinson’s symptoms. They may smooth out the fluctuations of mobility that occur over time. Agonists may also be used as initial therapy to delay the need for Sinemet. They are started at low doses and increased gradually over several weeks before therapeut ...
... when additional help is needed to control Parkinson’s symptoms. They may smooth out the fluctuations of mobility that occur over time. Agonists may also be used as initial therapy to delay the need for Sinemet. They are started at low doses and increased gradually over several weeks before therapeut ...
REMERON ® (mirtazapine) Tablets
... the N-desmethyl and N-oxide metabolite. Mirtazapine has an absolute bioavailability of about 50%. It is eliminated predominantly via urine (75%) with 15% in feces. Several unconjugated metabolites possess pharmacological activity but are present in the plasma at very low levels. The (–) enantiomer h ...
... the N-desmethyl and N-oxide metabolite. Mirtazapine has an absolute bioavailability of about 50%. It is eliminated predominantly via urine (75%) with 15% in feces. Several unconjugated metabolites possess pharmacological activity but are present in the plasma at very low levels. The (–) enantiomer h ...
Pharmacy Updates in Cardiology
... rates of major bleeding 150mg group was associated with LOWER rates of stroke and systemic embolism with similar rates of major bleeding with Warfarin ...
... rates of major bleeding 150mg group was associated with LOWER rates of stroke and systemic embolism with similar rates of major bleeding with Warfarin ...
Inhaled Drugs beyond Bronchodilators
... hypertonic group had even better lung function also, the hypertonic saline group had fewer lung infections. Average dose 4 mL You should not mix any other medications with hypertonic saline. Side effects that were noted included coughing more, sore throat and chest tightness. (It is known that hyper ...
... hypertonic group had even better lung function also, the hypertonic saline group had fewer lung infections. Average dose 4 mL You should not mix any other medications with hypertonic saline. Side effects that were noted included coughing more, sore throat and chest tightness. (It is known that hyper ...
Avalide (irbesartan hydrochlorothiazide)
... 618 patients were ≥ 65 years of age. No overall age-related differences were seen in the adverse effect profile but greater sensitivity in some older individuals cannot be ruled out. ...
... 618 patients were ≥ 65 years of age. No overall age-related differences were seen in the adverse effect profile but greater sensitivity in some older individuals cannot be ruled out. ...
Medicines for the Treatment of Obesity
... Weight loss was relatively modest. However, the hormone needs to be given subcutaneously and has a short half-life. Thus a modified recombinant human leptin (m-leptin) was created that has a longer half-life. ...
... Weight loss was relatively modest. However, the hormone needs to be given subcutaneously and has a short half-life. Thus a modified recombinant human leptin (m-leptin) was created that has a longer half-life. ...
Medicines for the Treatment of Obesity
... Weight loss was relatively modest. However, the hormone needs to be given subcutaneously and has a short half-life. Thus a modified recombinant human leptin (m-leptin) was created that has a longer half-life. ...
... Weight loss was relatively modest. However, the hormone needs to be given subcutaneously and has a short half-life. Thus a modified recombinant human leptin (m-leptin) was created that has a longer half-life. ...
32. MaryAnn O Hara et al. A review of 12 commonly used medicinal
... ably the best compendium of clinical information about herbs in the world, it does not disclose the scientific basis for its conclusions. Nevertheless, such guidelines provide hypotheses to prompt quality human trials, optimally with randomized, double-blind, placebo-controlled (RDBPC) trials. Resea ...
... ably the best compendium of clinical information about herbs in the world, it does not disclose the scientific basis for its conclusions. Nevertheless, such guidelines provide hypotheses to prompt quality human trials, optimally with randomized, double-blind, placebo-controlled (RDBPC) trials. Resea ...
A O
... an extensive study of the NTP feeding Oxymetholone; 350 and 160 mg/kg doses for 16 days caused weight gain in female rats and Oxymetholone; well fed 30 mg/kg of 2 years has caused weight gain in female rats. In another study in 2003 showed that men and women with AIDS and 100 daily 150mg/k g medicin ...
... an extensive study of the NTP feeding Oxymetholone; 350 and 160 mg/kg doses for 16 days caused weight gain in female rats and Oxymetholone; well fed 30 mg/kg of 2 years has caused weight gain in female rats. In another study in 2003 showed that men and women with AIDS and 100 daily 150mg/k g medicin ...
Bain 2006 - American Geriatrics Society
... use of these agents remain to be determined. Although they are among the groups with the greatest need for treatment, elderly patients with chronic insomnia are often viewed as difficult to treat. More research is needed to determine the long term effects of pharmacotherapy and the most appropriate ...
... use of these agents remain to be determined. Although they are among the groups with the greatest need for treatment, elderly patients with chronic insomnia are often viewed as difficult to treat. More research is needed to determine the long term effects of pharmacotherapy and the most appropriate ...
Saw Palmetto Botany
... Clinical Trials • Clinical trials have shown similar effects on LH as those produced in the laboratory. • Another clinical trial resulting in significant reductions in LH secretion and nonsignificant reductions in FSH. • Changes were not significantly different than those produce by standard œstroge ...
... Clinical Trials • Clinical trials have shown similar effects on LH as those produced in the laboratory. • Another clinical trial resulting in significant reductions in LH secretion and nonsignificant reductions in FSH. • Changes were not significantly different than those produce by standard œstroge ...
Bilastine
Bilastine (trade name Bilaxten) is a second generation antihistamine drug for the treatment of allergic rhinoconjunctivitis and urticaria (hives).It exerts its effect as a selective histamine H1 receptor antagonist, and has a effectiveness similar to cetirizine, fexofenadine and desloratadine. It was developed in Spain by FAES Farma.Bilastine is approved in the European Union for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria, but it is not approved by the U.S. Food and Drug Administration for any use in the United States. Bilastine meets the current European Academy of Allergy and Clinical Immunology (EAACI) and Allergic Rhinitis and its Impact of Asthma (ARIA) criteria for medication used in the treatment of allergic rhinitis.Bilastine has been effective in the treatment of ocular symptoms and diseases of allergies, including rhinoconjuctivitis. Additionally, bilastine has been shown to improve quality of life, and all nasal and ocular symptoms related to allergic rhinitis.